Arbutus Biopharma Corp. Announces 2024 Annual General and Special Meeting
Ticker: ABUS · Form: DEF 14A · Filed: Apr 10, 2024 · CIK: 1447028
| Field | Detail |
|---|---|
| Company | Arbutus Biopharma Corp (ABUS) |
| Form Type | DEF 14A |
| Filed Date | Apr 10, 2024 |
| Risk Level | low |
| Pages | 15 |
| Reading Time | 18 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: Proxy Statement, Annual Meeting, Shareholder Vote, Virtual Meeting, Arbutus Biopharma
TL;DR
<b>Arbutus Biopharma Corporation invites shareholders to its virtual 2024 Annual Meeting on May 22, 2024, urging prompt voting.</b>
AI Summary
Arbutus Biopharma Corp (ABUS) filed a Proxy Statement (DEF 14A) with the SEC on April 10, 2024. Arbutus Biopharma Corporation will hold its 2024 Annual General and Special Meeting of Shareholders on May 22, 2024. The meeting will be conducted solely via live audio webcast online at http://www.virtualshareholdermeeting.com/ABUS2024. Shareholders are urged to vote promptly due to potential broker non-votes on director elections and other non-routine matters. Proxy materials, including the Proxy Statement and Annual Report for the year ended December 31, 2023, are available electronically. The company was formerly known as Tekmira Pharmaceuticals Corp.
Why It Matters
For investors and stakeholders tracking Arbutus Biopharma Corp, this filing contains several important signals. Shareholders need to actively vote to ensure their shares are represented, as brokers may not vote uninstructed shares on key matters. The virtual format requires shareholders to access the meeting online, necessitating advance awareness and potential technical preparation.
Risk Assessment
Risk Level: low — Arbutus Biopharma Corp shows low risk based on this filing. This filing is a routine proxy statement for an annual shareholder meeting and does not contain new financial or operational information that would indicate significant risk.
Analyst Insight
Shareholders should review the proxy materials and vote their shares prior to the May 22, 2024 meeting to ensure their voice is heard on important corporate matters.
Key Numbers
- May 22, 2024 — Annual Meeting Date (Date of the 2024 Annual General and Special Meeting of Shareholders)
- 10:00 a.m. EDT — Meeting Time (Start time of the Annual Meeting)
- December 31, 2023 — Fiscal Year End (End date of the most recent fiscal year for which the Annual Report is available)
Key Players & Entities
- Arbutus Biopharma Corporation (company) — Registrant name
- May 22, 2024 (date) — Annual Meeting date
- Frank Torti, M.D. (person) — Chairman of the Board of Directors
- Tekmira Pharmaceuticals Corp (company) — Former company name
- 2024 (date) — Meeting year
FAQ
When did Arbutus Biopharma Corp file this DEF 14A?
Arbutus Biopharma Corp filed this Proxy Statement (DEF 14A) with the SEC on April 10, 2024.
What is a DEF 14A filing?
A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by Arbutus Biopharma Corp (ABUS).
Where can I read the original DEF 14A filing from Arbutus Biopharma Corp?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Arbutus Biopharma Corp.
What are the key takeaways from Arbutus Biopharma Corp's DEF 14A?
Arbutus Biopharma Corp filed this DEF 14A on April 10, 2024. Key takeaways: Arbutus Biopharma Corporation will hold its 2024 Annual General and Special Meeting of Shareholders on May 22, 2024.. The meeting will be conducted solely via live audio webcast online at http://www.virtualshareholdermeeting.com/ABUS2024.. Shareholders are urged to vote promptly due to potential broker non-votes on director elections and other non-routine matters..
Is Arbutus Biopharma Corp a risky investment based on this filing?
Based on this DEF 14A, Arbutus Biopharma Corp presents a relatively low-risk profile. This filing is a routine proxy statement for an annual shareholder meeting and does not contain new financial or operational information that would indicate significant risk.
What should investors do after reading Arbutus Biopharma Corp's DEF 14A?
Shareholders should review the proxy materials and vote their shares prior to the May 22, 2024 meeting to ensure their voice is heard on important corporate matters. The overall sentiment from this filing is neutral.
Risk Factors
- Proxy Voting Rules [medium — regulatory]: Shareholders must vote their shares as brokers may not vote uninstructed shares on non-routine matters, impacting director elections.
Key Dates
- 2024-05-22: Annual General and Special Meeting — Shareholders will vote on corporate matters and elect directors.
- 2024-04-10: Filing Date — The proxy statement was filed with the SEC.
Glossary
- Proxy Statement
- A document filed with the SEC that provides shareholders with information about matters to be voted on at a shareholder meeting. (Essential for shareholders to understand proposals and make informed voting decisions.)
- Annual General and Special Meeting
- A yearly meeting where shareholders discuss company business, vote on proposals, and elect directors. (The primary forum for shareholder engagement and corporate governance.)
- Broker Non-Vote
- A situation where a broker holding shares in 'street name' does not vote those shares on a particular proposal because they lack instructions from the beneficial owner and the proposal is non-routine. (Highlights the importance of direct shareholder voting to ensure representation on critical issues.)
Filing Stats: 4,606 words · 18 min read · ~15 pages · Grade level 12.1 · Accepted 2024-04-10 16:05:48
Filing Documents
- ny20020406x1_def14.htm (DEF 14A) — 1193KB
- ny20020406x1_barchart01.jpg (GRAPHIC) — 194KB
- ny20020406x1_barchart02.jpg (GRAPHIC) — 201KB
- sig_franktortimd.jpg (GRAPHIC) — 19KB
- ny20020406x1_pc01.jpg (GRAPHIC) — 700KB
- ny20020406x1_pc02.jpg (GRAPHIC) — 543KB
- 0001140361-24-019091.txt ( ) — 3474KB
EXECUTIVE COMPENSATION
EXECUTIVE COMPENSATION ​ ​ 35 DIRECTOR COMPENSATION ​ ​ 46 SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION PLANS ​ ​ 48 RELATED PARTY TRANSACTIONS ​ ​ 50 INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM ​ ​ 51 REPORT OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS ​ ​ 52 ADDITIONAL INFORMATION ​ ​ 53 DELIVERY OF PROXY MATERIALS TO HOUSEHOLDS ​ ​ 54 NOTICE TO SHAREHOLDERS IN THE UNITED STATES ​ ​ 54 SOLICITATION OF PROXIES ​ ​ 54 APPROVAL OF MANAGEMENT PROXY CIRCULAR AND PROXY STATEMENT ​ ​ 54 EXHIBIT A CORPORATE GOVERNANCE GUIDELINES ​ ​ 55 ANNEX A – 2016 OMNIBUS SHARE AND INCENTIVE PLAN, AS AMENDED ​ ​ A-1 TABLE OF CONTENTS QUESTIONS AND ANSWERS ABOUT THE PROXY MATERIALS AND VOTING What is the purpose of this Proxy Statement/Circular and the 2023 Annual Report to Shareholders? Our Board is soliciting your proxy to vote at the Annual Meeting, which will be held solely by means of live audio webcast online at www.virtualshareholdermeeting.com/ABUS2024, on Wednesday, May 22, 2024, at 10:00 a.m. (Eastern Daylight Time). This Proxy Statement/Circular contains important information about the matters to be voted on at the Annual Meeting, the voting process, the compensation of our directors and certain of our executive officers, corporate governance matters, and certain other required information. Our 2023 Annual Report to Shareholders, which consists of our Annual Report on Form 10-K for the year ended December 31, 2023 (the “Annual Report”), contains information about our business, our audited financial statements and other important information that we are required to disclose under the SEC’s rules. As many of our Shareholders may be unable to virtually attend the Annual Meeting, proxies a